Bingham Osborn & Scarborough LLC purchased a new stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, Holdings Channel reports. The fund purchased 7,202 shares of the pharmaceutical company’s stock, valued at approximately $311,000.

Several other institutional investors have also recently modified their holdings of GSK. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after buying an additional 2,482,009 shares during the period. Thrivent Financial For Lutherans boosted its position in shares of GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after buying an additional 1,371,490 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares during the last quarter. Bank of America Corp DE boosted its position in shares of GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares during the last quarter. Institutional investors own 8.96% of the company’s stock.

GlaxoSmithKline PLC (GSK) opened at 38.79 on Friday. The stock has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03. The stock’s 50 day moving average price is $41.84 and its 200-day moving average price is $41.84. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a dividend yield of 5.06%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

TRADEMARK VIOLATION NOTICE: “Bingham Osborn & Scarborough LLC Takes Position in GlaxoSmithKline PLC (GSK)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/13/bingham-osborn-scarborough-llc-takes-position-in-glaxosmithkline-plc-gsk.html.

A number of brokerages recently issued reports on GSK. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Friday, June 16th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. Finally, Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.